Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.55
-1.2%
$3.12
$7.96
$24.15
$12.86M0.6315,234 shs65,226 shs
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$1.99
-1.5%
$1.51
$1.09
$7.66
$143.43M2.941.32 million shs1.33 million shs
Replimune Group, Inc. stock logo
REPL
Replimune Group
$10.77
+3.7%
$9.09
$6.44
$17.00
$800.93M0.61888,578 shs2.27 million shs
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$9.06
-1.2%
$8.94
$5.04
$15.36
$459.97M1.06930,823 shs476,252 shs
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.30
$0.13
$0.01
$6.17
$541K0.966,759 shsN/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-1.15%0.00%-21.82%-66.54%-85.45%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
+18.13%+32.89%+20.24%+66.94%-59.60%
Replimune Group, Inc. stock logo
REPL
Replimune Group
+11.24%+8.80%+2.06%+50.14%+18.07%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
+4.92%+6.38%-3.78%+69.50%-13.41%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%0.00%+500.00%-72.73%-92.17%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
1.4843 of 5 stars
3.31.00.00.00.61.70.6
Replimune Group, Inc. stock logo
REPL
Replimune Group
4.1153 of 5 stars
3.61.00.04.52.02.50.6
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
4.3973 of 5 stars
3.43.00.04.61.43.30.6
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
2.50
Moderate Buy$12.00503.02% Upside
Replimune Group, Inc. stock logo
REPL
Replimune Group
3.13
Buy$20.8393.44% Upside
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
2.83
Moderate Buy$31.63249.06% Upside
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TBIO, CCCC, ALVR, REPL, and RGNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00
6/20/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
6/9/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$52.00
6/2/2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$14.00 ➝ $22.00
4/17/2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $12.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
$35.58M3.97N/AN/A$3.06 per share0.65
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/A$5.40 per shareN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$83.33M5.45N/AN/A$5.24 per share1.73
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share2.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/A-71.03%-61.27%8/7/2025 (Estimated)
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$105.32M-$1.47N/AN/AN/A-259.60%-45.86%-28.96%7/30/2025 (Estimated)
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$247.30M-$3.07N/AN/AN/AN/A-57.98%-45.21%8/14/2025 (Estimated)
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$227.10M-$3.11N/AN/AN/A-100.62%-53.29%-30.84%8/7/2025 (Estimated)
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%8/5/2025 (Estimated)

Latest TBIO, CCCC, ALVR, REPL, and RGNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.41N/AN/AN/A$5.24 millionN/A
8/7/2025Q2 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
-$1.13N/AN/AN/AN/AN/A
5/22/2025Q4 2025
Replimune Group, Inc. stock logo
REPL
Replimune Group
-$0.75-$0.82-$0.07-$0.82N/AN/A
5/12/2025Q1 2025
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
$0.41$0.12-$0.29$0.12$105.35 million$89.01 million
5/7/2025Q1 2025
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
-$0.48-$0.37+$0.11-$0.37$3.54 million$7.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/AN/AN/AN/AN/A
Replimune Group, Inc. stock logo
REPL
Replimune Group
N/AN/AN/AN/AN/A
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
N/A
5.70
5.70
Replimune Group, Inc. stock logo
REPL
Replimune Group
0.17
7.95
7.95
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
N/A
2.93
2.93
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
78.81%
Replimune Group, Inc. stock logo
REPL
Replimune Group
92.53%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
88.08%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
8.73%
Replimune Group, Inc. stock logo
REPL
Replimune Group
8.80%
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
12.79%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionOptionable
C4 Therapeutics, Inc. stock logo
CCCC
C4 Therapeutics
15071.01 million64.81 millionOptionable
Replimune Group, Inc. stock logo
REPL
Replimune Group
21077.09 million70.30 millionOptionable
REGENXBIO Inc. stock logo
RGNX
REGENXBIO
37050.16 million43.75 millionOptionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable

Recent News About These Companies

Telesis Bio: Q3 Earnings Snapshot
Telesis Bio Announces Departure of Chief Legal Officer
Telesis Bio Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.55 -0.03 (-1.16%)
As of 07/9/2025

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

C4 Therapeutics stock logo

C4 Therapeutics NASDAQ:CCCC

$1.99 -0.03 (-1.49%)
Closing price 04:00 PM Eastern
Extended Trading
$1.96 -0.03 (-1.76%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Replimune Group stock logo

Replimune Group NASDAQ:REPL

$10.77 +0.38 (+3.66%)
Closing price 04:00 PM Eastern
Extended Trading
$10.81 +0.04 (+0.37%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

REGENXBIO stock logo

REGENXBIO NASDAQ:RGNX

$9.06 -0.11 (-1.20%)
Closing price 04:00 PM Eastern
Extended Trading
$8.64 -0.43 (-4.69%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.30 0.00 (0.00%)
As of 07/8/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.